Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + Cyclophosphamide + Dexamethasone in NDMM and RRMM
NCT02046070Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of ixazomib in multiple myeloma (MM) (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants and Overall Response Rate (ORR) in Relapsed and/or Refractory Multiple Myeloma (RRMM) Participants. Started Mar 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02046070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046070.